Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
pulmonary arterial hypertension
Biotech
Merck posts fresh sotatercept data ahead of FDA approval ruling
Merck provided further safety and efficacy data ahead of a FDA ruling on whether to approve the jewel of its $11.5 billion Acceleron Pharma buyout.
Nick Paul Taylor
Sep 11, 2023 7:45am
Gossamer cuts loose staff, ties future to tarnished Merck rival
May 10, 2023 6:30am
Gossamer pauses CNS med enrollment, citing risk-benefit profile
Mar 17, 2023 11:16am
Gossamer touts phase 2 win but investors are wary
Dec 6, 2022 11:09am
Merck nails phase 3 sotatercept win a year after acquiring it
Oct 10, 2022 6:45am
InCarda, physIQ and Syneos team for phase 3 flecainide study
Aug 31, 2022 9:22am